Desloratadine canon tab n / 5mg film about 10 pc

Description

Composition
Active substance:
1 tablet contains: 5 mg desloratadine ;.
Excipients:
Calcium hydrogen phosphate dihydrate 61.7 mg; Povidone 6.8 mg; Calcium stearate 0.7 mg; croscarmellose sodium (primelloza) 4.8 mg; microcrystalline cellulose 41 mg; composition of the film coating: Opadry II White 4 mg, including: 1.88 mg of polyvinyl alcohol, macrogol (polyethylene glycol 3350) 0.94 mg talc 0.7 mg titanium dioxide 0.48 mg.
Description:
The tablets are round, biconvex, film-coated white or nearly white. The cross sectional almost white white or c kremovatam white or pinkish color.
Product form:
Tablets, film-coated, 5 mg.
At 7, 10 or 30 tablets in blisters of PVC film and aluminum foil printed patent.
1, 2, 3 blisters to 7 or 10 tablets, or 1, 2 blisters of 30 tablets together with instructions for use placed in a pile of cardboard.
Contraindications
-Increased sensitivity to any of the substances included in the preparation; -Pregnancy and lactation; -Age to 12 years.
Precautions: severe chronic renal failure.
Dosage
5 mg
Indications
-allergichesky rhinitis (elimination or alleviation of sneezing, nasal congestion, nasal mucus, itching nose, palate pruritus, itching and redness of the eyes, tearing); -krapivnitsa (reduction or elimination of itching, rashes).
Interaction with other drugs
The interaction with other drugs is not revealed. Eating does not affect the efficacy of the drug. Desloratadine does not increase the alcohol effects on the central nervous system.
Overdose
Symptoms. Receiving dose exceeding the recommended 5 times, does not cause any symptoms. In clinical trials, daily application for adults and adolescents desloratadine at a dose of 20 mg for 14 days is not associated with a statistically or clinically significant changes of the cardiovascular system. At clinical-pharmacological study of the use of desloratadine in a dose of 45 mg per day (at 9 times the recommended dose) for 10 days did not cause QT interval elongation and the appearance was not accompanied by serious side effects.
Treatment. In case of accidental ingestion of large amounts of the drug should contact a doctor immediately. Recommended gastric lavage, administration of activated charcoal; if necessary – symptomatic therapy. Desloratadine does not appear in hemodialysis, peritoneal dialysis efficacy has not been established.
pharmachologic effect
Pharmacological group:
Antiallergic agent – H1-histamine receptor blocker.
Pharmacodynamics:
Long-acting antihistamine. It is the primary active metabolite of loratadine. Inhibits the cascade of allergic inflammation, including release of pro-inflammatory cytokines including the interleukins IL-4, IL-6, IL-8, IL-13, the release of proinflammatory chemokines (RANTES), the production of superoxide anion by activated polymorphonuclear neutrophils adhesion and chemotaxis eosinophils, selection adhesion molecules such as P-selectin,
IgE-mediated release of histamine, prostaglandin D2 and leukotriene C4. Thus, it prevents the development and facilitates the allergic reactions, and possesses protivoekssudativnoe antipruritic effect, reduces capillary permeability, prevents the development of edema, smooth muscle spasm.
The drug has no effect on the central nervous system with practically no sedative effect (does not cause drowsiness) and does not affect the speed of psychomotor reactions. It does not cause QT prolongation on the ECG.
Action desloratadine starts within 30 minutes after oral administration and lasts 24 hours.
Pharmacokinetics:
Desloratadine is well absorbed in the gastrointestinal tract. Determined in blood plasma within 30 minutes after ingestion. The maximum concentration is achieved after an average of 3 hours after ingestion. It does not cross the blood-brain barrier. Communication plasma protein is 83-87%. In the application for adults and adolescents over 14 days in a dose of 5 mg to 20 mg 1 time per day clinically significant drug accumulation is not observed. Simultaneous food intake or grapefruit juice does not affect the distribution of desloratadine at an application rate of 7.5 mg 1 time per day.
Desloratadine not an inhibitor of CYP3A4 and CYP2D6, and is not a substrate or inhibitor of P-glycoprotein. It is extensively metabolized in the liver by hydroxylation to form 3-OH-desloratadine connected to glucuronide. Only a small part of an oral dose is excreted by the kidneys (
Pregnancy and breast-feeding
The drug Desloratadine Canon is not recommended during pregnancy, as the relevant clinical studies have been conducted and the safety of use during pregnancy has not been established.
Desloratadine passes into breast milk, so breastfeeding women should not take the drug Desloratadine Canon.
Conditions of supply of pharmacies
Without recipe.
side effects
Classification of the WHO frequency of side effects: very often -> 1/10 assignments (> 10%) frequently – by> 1/100 to 1%, and
special instructions
Research on the effectiveness of desloratadine in rhinitis infectious etiology have been conducted.
Effect on the driving ability and other mechanical means
Adverse effects on the management of the car or appliances have been noted.
Storage conditions
In a dry, dark place at a temperature not higher than 25 C.
Keep out of the reach of children.
Dosing and Administration
Inside, regardless of meals, in adults and adolescents from 12 years: 1 tablet per day. Tablets should be swallowed whole with water.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist